Maxygen, Inc. (MAXY) Announces Global Development Agreement with Astellas Pharma, Inc.
Maxygen, Inc. (NASD: MAXY), a biopharmaceutical company focused on developing improved versions of protein drugs, recently announced a global agreement with Astellas Pharma Inc., a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The agreement, in which Astellas will receive worldwide rights to commercialize MAXY-4 lead candidates for all autoimmune diseases and transplant rejection, represents a significant step. MAXY-4 is Maxygen’s preclinical program to create a next-generation CTLA4-Ig protein for rheumatoid arthritis, transplant rejection and other autoimmune indications. The companies will co-develop MAXY-4 candidates for rheumatoid arthritis…